BioLife Corp (BLFS): Price to Sales
BioLife Solutions, Inc. (BLFS) maintains a stable cash flow driven by the integration of its media into FDA regulations. The current P/S multiple illustrates this resilience, with 18.40 defining the current value of the metric. Revenue is based on the sale of laboratory systems and cryopreservation media. The brand's impeccable authority in the gene therapy sector guarantees maximum B2B partner loyalty and supply reliability.
Analytical breakdowns for BioLife Corp (BLFS)
- price and consensus price forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Capital BioLife Solutions, Inc.|BLFS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient BioLife|BLFS - Company Debts|Debts to Book Value BioLife Corp|BLFS - Company Long-Term Debt|Company Short-Term Indebtedness BioLife Solutions|Interim Coverage Ratio biolifesolutions.com
- financial results and valuation multiples details:
BLFS - Net Income|Expected Net Income BioLife Solutions, Inc.|BLFS - P/E Multiple|Market Cap to Projected Earnings BioLife Solutions Inc|BLFS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation BioLife Corp|BLFS - Operating profit EBITDA|Net earnings per share for the last 12 months BioLife Solutions|BLFS - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months biolifesolutions.com|BLFS - Earnings growth in current year|Net earnings per share growth forecast for next year BioLife Solutions, Inc.
- sales revenue and business income indicators:
Fundamental company analysis:BLFS - biolifesolutions.com
The P/S ratio correlates the market value of the business with its annual revenue, allowing for an assessment of real demand for shares regardless of current profitability. Analyzing the price-to-sales ratio helps filter out speculative noise, confirming the value of BioLife Solutions, Inc. (BLFS) through stable revenue from cell storage consumables, which create long-term customer dependency on the company's infrastructure.
Competitors of BioLife Solutions, Inc.
Price-to-Revenue Coefficient Tempus AI|Price-to-Revenue Ratio Qiagen QGEN|Ionis Pharmaceuticals, Inc. (IONS) - Price to Sales|RGEN - Price-to-Revenue Ratio|RNA: Price-to-Revenue Ratio|CRSP (CRISPR Therapeutics AG) - Market Cap to Revenue|genedx.com (WGS) - P/S Multiple|Market Cap to Revenue RARE|BEAM (Beam Therapeutics Inc) - Market Cap to Sales Volume|P/S Multiple SRPT|Price-to-Revenue Coefficient Twist Bioscience Corp|Price-to-Revenue Ratio 10x Genomics, Inc. TXG|intelliatx.com (NTLA) - Price to Sales|STOK - Price-to-Revenue Ratio|WVE (Wave Life Sciences Ltd) - Market Cap to Revenue Ratio|Maze Tx (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|Market Cap to Revenue PRME|TSHA: Market Capitalization-to-Revenue Ratio|P/S Multiple QURE|Price-to-Revenue Coefficient MeiraGTx Holdings|Price-to-Revenue Ratio Regenxbio RGNX|SLDB: Market Cap to Revenue Ratio|Ocugen, Inc. - P/S Multiple|pacb.com (PACB) - Market Cap to Revenue|BNTC (Benitec Biopharma) - Market Cap to Revenue|DSGN - Price-to-Revenue Coefficient|RCKT (Rocket Pharmaceuticals Inc) - P/S Multiple|Price-to-Revenue Ratio FDMT|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|Price-to-Revenue Ratio KRRO (korrobio.com)|P/S Multiple EDIT (Editas Medicine)|SLN (Silence Therapeutics PLC) - Price-to-Sales Ratio|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis, Inc. CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio Metagenomi|Market Cap to Revenue Ratio DTIL (precisionbiosciences.com)|P/S Multiple GBIO|P/S Multiple Boundless Bio Inc (BOLD)|P/S Multiple XCUR (Exicure)|Imunon Inc - Price-to-Revenue Ratio|RXi Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient Mustang Bio, Inc. MBIO|transcodetherapeutics.com (RNAZ) - Price-to-Revenue Ratio|Price to Sales Bionano Genomics (BNGO)|Price-to-Revenue Ratio Applied DNA Sciences|Price-to-Revenue Ratio BLUE|P/S Multiple IPA|Price-to-Revenue Coefficient Omega Therapeutics Inc|P/S Multiple OMIC (Singular Genomics Systems Inc)|RGLS (Regulus) - Price-to-Sales Ratio|Syros Pharmaceuticals - P/S Multiple|Price to Sales telesisbio.com|TCON (TRACON Pharmaceuticals, Inc.) - Market Cap to Revenue|Unity Biotechnology Inc. - Market Capitalization-to-Revenue Ratio
